Lung Cancer Clinical Trial
— DOLCEOfficial title:
DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction (LCP) Artificial Intelligence Solution on Service Utilisation, Health Economics and Patient Outcomes
NCT number | NCT05389774 |
Other study ID # | 21RM052 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 23, 2023 |
Est. completion date | August 2024 |
Verified date | March 2024 |
Source | Nottingham University Hospitals NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is a multi-centre prospective observational cohort study recruiting patients with 5-30mm solid and part-solid pulmonary nodules that have been detected on CT chest scans performed as part of routine practice. The aim is to determine whether physician decision making with the AI-based LCP tool, generates clinical and health-economic benefits over the current standard of care of these patients.
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | August 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Years and older |
Eligibility | Inclusion Criteria: Patients are eligible for the study if all of the following apply: - Are aged 35 years or above - Have baseline CT study with at least one incidentally detected solid or part-solid (must have a solid component >=80%) pulmonary nodule that: - is not fully calcified - Is 5-30mm inclusive in maximum axial diameter for the whole lesion measured using manual electronic callipers - Have baseline CT study that includes at least one series that meets all of the following (training for this will be provided): - Is of a type that meets VNC instructions for use - Comprises at least one full-inspiration breath-hold scans without a high degree of contrast media and does not exhibit quality issues (e.g., motion artefacts) Exclusion Criteria: Patients will be excluded from the study if any of the following apply: - Have received a diagnosis for cancer in the last 5 years - Have thoracic implants that impact the image appearance of the nodule - Have more than five reported pulmonary nodules of any size or type excluding fully calcified nodules (this criterion is used as a proxy due to the risk of being an infection or metastasis) - Have one or more additional nodules where any of the following applies: - Are already undergoing follow-up according to pulmonary nodule management standard care - Pure ground glass opacity (GGO) of >=5mm in maximum axial diameter for the whole lesion measured using manual electronic callipers - >30mm in maximum axial diameter for the whole lesion measured using manual electronic callipers |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Betsi Cadwaladr University Health Board | Bangor | |
United Kingdom | Frimley Health NHS Foundation Trust (Wexham Park Hospital) | Frimley | |
United Kingdom | Leeds Teaching Hospitals NHS Trust | Leeds | |
United Kingdom | University Hospitals of Leicester NHS Trust | Leicester | |
United Kingdom | King's College Hospital NHS Foundation Trust | London | |
United Kingdom | Royal Free Hospital | London | |
United Kingdom | St. George's University Hospitals NHS Foundation Trust | London | |
United Kingdom | The Royal Marsden NHS Foundation Trust | London | |
United Kingdom | University College London Hospitals NHS Foundation Trust | London | |
United Kingdom | Nottingham University Hospitals NHS Trust | Nottingham | |
United Kingdom | Oxford University Hospitals NHS Foundation Trust | Oxford |
Lead Sponsor | Collaborator |
---|---|
Nottingham University Hospitals NHS Trust | Optellum Ltd. |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the potential effect of the LCP on discharge | Measured difference between standard care, LCP and LCP-guided care for:
Percentage of cancer patients discharged (straight after assessment of the baseline scan) Percentage of benign-nodule patients discharged (straight after assessment of the baseline scan) |
up to 1 year. | |
Secondary | Determine the potential effect of the LCP on overall clinical management, as well as scan and procedure utilization. | Percentage of cancer patients for whom there would have been a change in clinical management by LCP and LCP-guided care compared with the actual (standard) care (correctly by more aggressive management and incorrectly for less aggressive management).
Percentage of benign-nodule patients for whom there would have been a change in clinical management by LCP and LCP-guided care compared with the actual (standard) care (incorrectly by more aggressive management and correctly for less aggressive management). Measured difference between standard care, LCP and LCP-guided care for: Percentage of CT scans and PET/CT scans performed on benign-nodule patients Percentage of non-surgical biopsies performed on benign-nodule patients Percentage of surgical excisions on benign-nodule patients |
up to 1 year. | |
Secondary | Determine the potential effect of the hypothetical LCP-informed care versus standard care on patient outcomes. | Measured difference between standard care, LCP and LCP-guided care for:
Percentage of thoracic, respiratory or vascular events related to biopsies or surgical excisions for lung nodules or suspected lung cancer occurring within 30 days of the procedure on benign-nodule patients Percentage of lung cancers stratified by stage Time in days between nodule detection and lung cancer diagnosis |
up to 1 year. | |
Secondary | Determine the potential health-economic effect of the hypothetical LCP-informed care versus standard care | Measured difference between standard care, LCP and LCP-guided care for:
The composite standardized GBP costs of all healthcare-related activity for lung nodules or suspected lung cancer Health-related utilities (life years and QALYs) |
up to 1 year. | |
Secondary | Determine the potential effect of the LCP on possible adherence to clinical guidelines. | Measured difference between standard care and LCP-guided care for :
Number and percentage of patients for whom a validated risk model (Brock or LCP) is used to guide the next clinical management step (i.e., counting the instances where Brock is not used, or where LCP is not possible to compute or it is ignored). |
up to 1 year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|